A phase 1 study to assess BDTX-1535, an oral EGFR inhibitor, in patients with glioblastoma or non–small-cell lung cancer Meeting Abstract
| Authors: | Johnson, M. L.; Henry, J. T.; Spira, A. I.; Battiste, J.; Alnahhas, I.; Ahluwalia, M. S.; Barve, M. A.; Edenfield, W. J.; Nam, D. H.; Eathiraj, S.; Hajdenberg, J.; Yurasov, S.; Yu, H. A.; Wen, P. Y. |
| Abstract Title: | A phase 1 study to assess BDTX-1535, an oral EGFR inhibitor, in patients with glioblastoma or non–small-cell lung cancer |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.TPS9156 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: TPS9156 -- Meeting was also available virtually -- Source: Cinahl |
